A detailed history of Stanley Druckenmiller (Duquesne Family Office LLC) transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Duquesne Family Office LLC holds 536,900 shares of SBTX stock, worth $0. This represents 0.26% of its overall portfolio holdings.

Number of Shares
536,900
Holding current value
$0
% of portfolio
0.26%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
N/A
536,900 New
536,900 $7.79 Million

Others Institutions Holding SBTX

About Silverback Therapeutics, Inc.


  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track Stanley Druckenmiller's Portfolio

Track Stanley Druckenmiller Portfolio

Follow Stanley Druckenmiller (Duquesne Family Office LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

News

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.